MedTrace Logo

Antiangiogenic Therapy of Choroidal Neovascularisation Associated With Central Chorioretinitis

NCT04245072 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2021-02-03

No results posted yet for this study

Summary

The purpose of this study is to determine the effectiveness of antiangiogenic therapy to choroidal neovascularization secondary to central chorioretinitis.

Conditions

  • Chorioretinitis

Interventions

PROCEDURE

Intravitreal injection

Intravitreal injection of Aflibercept 2 mg (0.05 ml) or Ranibizumab 0.5 mg (0.05 ml) to the regimen pro re nata.

DIAGNOSTIC_TEST

Fluorescent angiography

Ophthalmic examination

DIAGNOSTIC_TEST

Visometry

Ophthalmic examination

DIAGNOSTIC_TEST

Refractometry

Ophthalmic examination

DIAGNOSTIC_TEST

Slit lamp examination

Ophthalmic examination

DIAGNOSTIC_TEST

Ophthalmoscopy

Ophthalmic examination

DIAGNOSTIC_TEST

OKT

Ophthalmic examination

Sponsors & Collaborators

  • Odessa National Medical University

    collaborator OTHER

  • Mykolaiv Region Ophthalmogical Hospital

    collaborator OTHER

  • Central Polyclinic of Internal Affairs of Ukraine

    collaborator OTHER_GOV

  • The Filatov Institute of Eye Diseases and Tissue Therapy

    lead OTHER

Principal Investigators

  • Andrii MD Korol, PhD · The Filatov Institute of Eye Diseases and Tissue Therapy

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-27
Primary Completion
2021-12-31
Completion
2022-01-31

Countries

  • Ukraine

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04245072 on ClinicalTrials.gov